Aspirin can cut by more than half the risk that colon cancer will come back following initial treatment, a new Karolinska Institute clinical trial found. File Photo by John Angelillo/UPI | License Photo
Aspirin can cut by more than half the risk that colon cancer will come back following initial treatment, a new clinical trial has found.
Daily aspirin reduced by 55% the risk of cancer recurrence in patients whose colorectal cancer is driven by a genetic mutation, researchers reported Wednesday in the New England Journal of Medicine.
"Aspirin is a drug that is readily available globally and extremely inexpensive compared to many modern cancer drugs, which is very positive," lead researcher Anna Martling, a professor of molecular medicine and surgery at Karolinska Institute in Sweden, said in a news release.
The study focused on people whose colon cancer was driven by a mutation of the PIK3 gene, which helps regulate cell growth and division in the human body.
